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Animal studies have demonstrated that altering the maternal diet during pregnancy affects
offspring disease risk. Data from human subjects on the early-life determinants of disease have
been derived primarily from birth-weight associations; studies of the impact of the maternal
diet are scarce and inconsistent. Investigating CVD risk factors in the offspring of women who
have participated in maternal supplementation trials provides a useful resource in this research
field, by virtue of employing an experimental design (as compared with observational studies).
To date, follow-up studies have been published only for a small number of trials; these trials
include the impact of maternal protein–energy, multiple-micronutrient and Ca supplementation
on offspring disease risk. In Nepal maternal micronutrient supplementation has been shown to
be associated with lower offspring systolic blood pressure at 2 years of age. Data from Gua-
temala on a pre- and postnatal protein–energy community intervention have suggested long-
term improvements in fasting glucose and body composition but not in blood pressure. In The
Gambia no association has been found between prenatal protein–energy supplementation and
markers of CVD risk including body composition, blood pressure and fasting glucose and
insulin in childhood and adolescence. Little evidence of an effect of maternal Ca supple-
mentation on offspring blood pressure has been demonstrated in four trials, although the risk of
high systolic blood pressure was found to be reduced in one trial. The present paper reviews the
current evidence relating maternal nutritional supplementation during pregnancy to offspring
CVD risk and explores the potential explanations for the lack of association.
Developmental origins of health and disease: Maternal supplementation trials: CVD risk
The field of research currently known as the developmental
origins of health and disease (DOHaD) grew from initial
observations that infant mortality rates at the turn of the
last century were highly correlated with standard mortality
rates approximately 60 years later(1,2). One explanation
given for these findings is that a ‘nutritional deficit’ oper-
ating in early life results in ‘a lifelong vulnerability to
aspects of an affluent adult lifestyle’(1). After 30 years the
field of DOHaD has grown into a vibrant multi-disciplinary
research area, although controversy remains about the
nature of the early-life nutritional deficits and the mech-
anisms through which they might affect later health.
CVD is one of the main diseases of affluence faced by
the world today. Evidence that CVD risk may be related to
early-life, specifically intrauterine, exposures was initially
derived from the inverse association between birth weight
and CVD mortality(3–5) and/or risk factors such as blood
pressure(6,7) insulin resistance(8) and the metabolic syn-
drome(9). One of the most-widely-cited hypotheses, termed
the ‘thrifty phenotype’(10), suggests that when exposed to
deprived conditions during development fetal adaptations
(metabolic, endocrine and/or anatomical) occur that allow
for immediate survival but may be maladapted to cope
with the demands of a more-affluent lifestyle in later life
Abbreviation: DOHaD, developmental origins of health and disease.
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(Fig. 1). Maternal nutrition is one of the potentially-
modifiable determinants of fetal nutrition and is thus a
focus of research seeking to understand the association
between early life and later disease.
A wealth of animal studies, extensively reviewed else-
where(11–13), have confirmed that perturbations in the ma-
ternal diet during pregnancy can have a profound impact
on offspring disease risk. Pregnant rats fed a low-protein
diet give birth to offspring that develop hypertension,
which persists into adult life(14). Indeed, some or all the
components of the metabolic syndrome can be produced
by a variety of maternal exposures, including global
nutrient restriction(15), placental insufficiency(16) and a
low-Fe diet(17) as well as a low-protein diet. The animal
data have allowed for increasingly sophisticated explor-
ation of potential mechanisms and have greatly enhanced
the DOHaD field. Nevertheless, the translation of these
findings into human studies remains challenging.
The majority of data from human subjects still centres
on the inverse association between birth weight and later
disease. These observations are primarily from retro-
spective cohort studies and the evidence base has been
criticised for inappropriate statistical methods(18), public-
ation bias and inadequate adjustment for socio-economic
status(19). Perhaps the most important criticism is that birth
weight is a poor measure of exposure, primarily as it is mul-
tifactorial in origin, prompting calls to move towards more
direct assessments of exposure. Studies relating maternal
diet in pregnancy and offspring CVD risk are rare, how-
ever, and have shown little or no associations to date(20,21).
Furthermore, cohort studies investigating diet during preg-
nancy retain many of the same study design issues as those
that have utilised birth weight. The Dutch Hunger Winter
Study (1944–5) has been used as a pseudo-experiment with
which to study the impact of nutritional deprivation during
pregnancy on offspring disease risk. Results focusing on
CVD risk have been inconsistent(22–24), however, and by
their nature the cohorts have widely-recognised design
issues; including large loss to follow-up and a lack of data
on individual dietary and/or nutrient intakes.
One emerging resource in this field is the follow up
of trials of maternal supplementation during pregnancy.
Although primarily conducted to evaluate the effectiveness
of interventions to improve pregnancy and birth outcomes,
these trials represent a useful resource for the DOHaD field
by providing randomised controlled trial data. To date, the
only exposures that have been studied in this manner are
protein–energy, multiple-micronutrient and Ca supplemen-
tation. The remainder of the present paper will summarise
these follow-up studies insofar as they relate to offspring
CVD risk.
Protein–energy
In the late 1960s the Institute of Nutrition of Central
America and Panama conducted a community trial of
protein supplementation in rural Guatemala. Two villages
received the ‘Atole’ supplement, a protein–energy-dense
drink, whilst two control villages received the ‘Fresco’
supplement, a drink that contained no protein and ap-
proximately one-third of the energy(25). The study design is
summarised in Table 1; supplement drinks were provided
twice daily and their consumption by pregnant women and
children up to the age of 7 years was recorded. A number
of follow-up studies have been conducted on the trial par-
ticipants and the findings have been extensively sum-
marised(26). Findings most relevant to CVD risk include a
marginally-greater fat-free mass in adolescent girls born in
intervention villages(27), reduced fasting glucose in 25-
year-old women born in intervention villages(28) but no
difference in blood pressure between individuals born in
intervention and control villages(29) (Table 2). A major lim-
itation of this study in relation to the current review is that
it is not possible to distinguish between pre- and postnatal
enhanced nutrition in the intervention analysis. Further-
more, because of the small number of villages the cluster
design of the original trial has not been accounted for in the
analysis. Although often viewed as a trial of protein sup-
plementation, the two drinks also provided different levels
of certain micronutrients (Ca, P, Zn, folic acid and vitamin
B12), which may affect interpretation of the results
(26).
The Barry Caerphilly Growth Study is a follow up of
children whose mothers took part in a trial to improve their
cow’s milk intake during pregnancy that was conducted in
South Wales, UK in the early 1970s(30) (Table 1). Women
were randomised to receive milk tokens throughout preg-
nancy and for the first 5 years of their child’s life or to
receive no tokens (control). Milk tokens were equivalent to
284ml milk/d from the milkman. At 25 years of age the
offspring were enrolled into a follow-up study and it was
found that those whose mothers had received the interven-
tion had lower serum levels of insulin-like growth factor 1
compared with those born to control mothers (Table 2)(30).
Insulin resistance(31) and IHD(32) have been associated with
low insulin-like growth factor 1 concentrations in obser-
vational studies. For the purposes of the present review
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Fig. 1. Schematic diagram of the ‘thrifty phenotype’ hypothesis
showing potential pathways to type 2 diabetes and hypertension.
(Adapted from Hales & Barker(10).)
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Table 1. Characteristics of trials and follow-up studies of maternal protein–energy supplementation
Guatemala Wales, UK The Gambia
Original trial Martorell et al.(25) Ben-Shlomo et al.(60) Ceesay et al.(33)
Design Community-level randomised trial, 1969–77 Randomised controlled trial, 1972–4 Community-level randomised trial, 1989–94
Randomisation Village level: two intervention villages, two ‘control’ Individual level using random number tables Village level: sixteen intervention and twelve
‘control’
Participants All village residents: intake of pregnant women and
children up to age 7 years recorded
Pregnant women from two towns in South
Wales attending primarycare clinics
Enrolled for pregnancy and until their child
was 5 years of age
All pregnant women in participating villages
From 20 weeks of gestation until term
Supplement Drink-based supplement, provided twice daily
in central location
Intervention villages: ‘Atole’; 682 kJ energy, 11.5 g protein
Control villages: ‘Fresco’; 247 kJ energy, 0 g protein
(consumed twice as frequently as Atole)
Milk tokens; entitled owner to free milk
delivery (equivalent to 284 ml/d)
Intervention arm: milk tokens
Control arm: no tokens
Two biscuits provided daily (4250 kJ energy),
22 g protein, 56 g fat, 47 mg Ca, 1.8 mg Fe
Intervention arm: biscuits from 20 weeks
gestation until delivery
Control arm: biscuits for 20 weeks
post partum
Follow-up Summary: Martorell(26)
Body composition: Rivera et al.(27)
Blood pressure: Webb et al.(29)
Glucose: Conlisk et al.(28)
Ben-Schlomo et al.(30) Blood pressure: Hawkesworth et al.(34)
Body composition: Hawkesworth et al.(35)
Date Rivera et al.(27): 1988–9; (subjects exposed
during pregnancy until 3 years of age)
Webb et al.(29) and Conlisk et al.(28) 1997–8
(subjects exposed during pregnancy until 7 years of age)
1997–9 2005–6
Age of offspring Rivera et al.(27): 14–20 years
Webb et al.(29) and Conlisk et al.(28): 20–29 years
Men: 23.2–27.2 years (mean 25 years)
Women: 23.1–26.8 years (mean 25 years)
11.2–17.0 years (mean 14.1 years)
Loss to follow-up Rivera et al.(27): 1574 of 2169 (73%) original trial
offspring recruited for entire follow-up
460 children (exposed during pregnancy and to
3 years of age) included in analysis
Webb et al.(29): 450 of 585 (77%) eligible and traceable
subjects; lost to follow-up associated with lower birth weight
Conlisk et al.(28): 478 of 585 (82%) eligible and
traceable subjects
633 of 1163 (54%) of original trial
offspring recruited
Lost to follow-up associated with lighter
birth weight and younger maternal age
1317 of 2047 (64%) of original trial offspring
recruited
No differences associated with lost to
follow-up
Outcomes Anthropometry
Fasted blood from fingerpick assessed for plasma glucose
Blood pressure (digital sphygmomanometer; UA-767;
A&D Instruments Ltd, Abington, Oxon., UK)
Fasted blood samples collected. Serum
levels of IGF-1, IGFBP-3 and IGF-1:
IGFBP-3 were determined
Blood pressure (Omron 705IT;
Morton Medical Ltd, London, UK)
Body composition (Tanita BC-418MA;
Chasmors Ltd, London, UK;
with population-specific equations(61))
Triceps skinfold thickness
Fasted blood sample analysed for glucose
and insulin
IGF, insulin-like growth factor; IGFBP-3, IGF-binding protein.
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Table 2. Effect of maternal protein–energy supplementation on CVD risk factors in the offspring from trials conducted in Guatemala(27–29), Wales, UK(30) and The Gambia(34,35)*
Outcome Study Gender
Supplement Control Mean differencek
Pn Mean SD or IQR n Mean SD or IQR Mean 95% CI
Blood pressure
Systolic (mmHg) Webb et al.(29) M 119 120 9.9 106 120 11.2 0.6 - 2.17, 3.37 0.67
F 109 103 9.2 116 104 11.4 - 0.5 - 3.23, 2.23 0.72
Hawkesworth et al.(34) 608 111 8.8 659 110 9.3 0.46{ - 1.12, 2.04 0.57
Diastolic (mmHg) Webb et al.(29) M 119 73.4 7.8 106 72.4 8.1 1.0 - 1.09, 3.09 0.35
F 109 65.6 7.7 116 64.6 8.0 1.0 - 1.07, 3.07 0.34
Hawkesworth et al.(34) 608 64.6 7.6 659 64.7 7.7 0.09{ - 1.31, 1.13 0.89
Body composition
Whole-body fat (%)† Hawkesworth et al.(35) M 315 12.6 2.8 337 12.6 3.0 0.01{ - 0.52, 0.55 0.96
F 288 19.5 4.7 321 19.3 4.3 0.19{ - 0.68, 1.06 0.67
FFM (kg)‡ Rivera et al.(27) M 118 42.5 3.3 127 42.3 3.4 0.2 - 0.64, 1.04 0.64
F 116 36.9 4.3 99 35.7 4.0 1.2 0.08, 2.32 0.04
Triceps skinfold
thickness (mm)
Hawkesworth et al.(35) M 321 6.4 1.9 338 6.3 2.0 - 0.1{ - 0.04, 0.06 0.68
F 290 11.0 5.0 321 10.8 4.5 0.003{ - 0.08, 0.08 0.92
Blood analysis
Fasted glucose (mmol/l) Hawkesworth et al.* 608 49.1 30.2 653 48.2 28.4 - 0.05{ - 0.10, 0.01 0.08
Conlisk et al.(28) M NR NR 0.02 - 0.29, 0.33 0.80
F NR NR 0.29 - 0.23, 0.80 0.03
Fasted insulin (pmol/l) Hawkesworth et al.* 607 4.8 0.5 655 4.9 0.4 0.62{ - 4.19, 5.42 0.80
IGF-1 (ng/ml) Ben-Shlomo et al.(30) 344 136§ 110–172 306 144§ 111–178 - 8.5** - 15.1, - 1.8 0.01
IGFBP-3 (g/ml) Ben-Shlomo et al.(30) 344 6.44§ 5.51–7.53 306 6.43§ 5.55–7.52 - 0.04** - 0.28, 0.21 0.73
IGF-1:IGFBP-3 Ben-Shlomo et al.(30) 344 21.8§ 17.1–26.1 306 22.9§ 17.6–28.5 - 1.2** - 2.33, - 0.04 0.04
FFM, fat-free mass; IGF, insulin-like growth factor; IGFBP-3, IGF-binding protein; M, males; F, females; NR, not reported; IQR, interquartile range.
*S Hawkesworth, AM Prentice, AJC Fulford and SE Moore (unpublished results).
†Whole-body fat assessed by bioelectrical impedance analysis utilising population-specific prediction equations.
‡Calculated from prediction equations using arm diameter for males and waist circumference for females.
§Because of skewness of data these values are the median and IQR.
kUnadjusted regression analysis unless otherwise stated.
{Generalised estimating equations used to take village clustering into account.
**Regression adjusted for age and gender.
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milk tokens have been viewed as a protein–energy sup-
plement, but it should be acknowledged that the increased
consumption of Ca and/or growth factors may also be
relevant.
In 2005 a follow-up study was conducted in The Gam-
bia, West Africa involving offspring (aged 11–17 years)
who had been born during a randomised trial of supple-
mentation with protein–energy-dense biscuits during preg-
nancy or lactation. The original trial(33) provides some of
the strongest evidence yet that protein–energy supplements
can improve birth weight in nutritionally-deprived popu-
lations. The trial used a cluster randomised design in
twenty-eight villages; pregnant women from intervention
villages received protein–energy-dense biscuits from 20
weeks of gestation until delivery whilst women in control
villages received the same supplement for 20 weeks post
partum. The supplement given during pregnancy was
shown to increase birth weight by 136 g overall, with a
greater difference of 201 g during the nutritionally-poor
‘hungry season’ (June–October)(33). The follow-up study
has found no evidence that these early-life differences cor-
respond to later differences in risk profile in the offspring;
no effect of maternal supplementation during pregnancy on
offspring blood pressure(34), body fat(35) or fasting insulin
and glucose was found (S Hawkesworth, AM Prentice,
AJC Fulford and SE Moore, unpublished results; Table 2).
The limitation of this study is that the women in the con-
trol arm were provided with the same protein–energy-
dense biscuits during lactation. However, as there is little
evidence to suggest that supplementation of lactating
women affects breast-milk quality or quantity(36,37) the
comparison is considered to be appropriate. Although no
overall effect of maternal protein–energy supplementation
on offspring CVD risk was found, an interaction with body
composition was found. For offspring who were relatively
lean (in the lowest quartile of percentage body fat) at fol-
low up the intervention was associated with raised systolic
blood pressure (Fig. 2). It is possible that providing sup-
plements to the mother whilst the fetus is developing pro-
vides better conditions than those that are experienced
postnatally, although only for offspring who remain parti-
cularly lean. This interaction may reflect the ‘mismatch’
theory, which suggests that if conditions during in utero
development are ‘mismatched’ to the later environment
this mismatch promotes the development of disease(38).
The pattern more often seen in the literature is the inter-
action between low birth weight and overweight in adult-
hood(38); in the less-developed setting of The Gambia it
seems that the reverse of this pattern may have been
observed.
Multiple micronutrients
In recent years there has been considerable interest in the
potential of maternal micronutrient supplementation during
pregnancy to provide important benefits for both the
mother and her infant. Recently, the results of the many
trials have been summarised, with the focus on short-term
outcomes such as birth weight and infant survival(39). Only
one trial has so far published findings of follow up beyond
infancy (Table 3), reporting lower systolic blood pressure
and slightly greater triceps skinfold thickness for 2–3-year-
old children born to Nepalese mothers who received a com-
bination of fifteen micronutrients compared with ‘control’
women receiving only Fe and folic acid(40) (Table 4). The
authors suggest caution in the interpretation of this finding
from a single trial and recognise the importance of repli-
cation in other studies(40). It should also be noted that there
was no difference in diastolic blood pressure, and that
blood pressure is notoriously difficult to measure in very
young children. Similar follow-up studies in Bangla-
desh(41) and a different area of Nepal(42) are currently
nearing completion and will soon add to the current limited
knowledge.
Calcium
A number of maternal Ca supplementation trials have been
conducted on pregnant women in recent years, primarily
to investigate the potential for reducing the risk of pre-
eclampsia(43,44). To date three trials have published follow-
up data on the offspring, focusing on blood pressure as
an outcome(45–47) (Table 5). The follow-up of a trial con-
ducted in the USA has provided evidence that maternal Ca
supplementation is associated with lower systolic blood
pressure in the offspring at 2 years, although only 10% of
eligible participants were recruited(46). Data from The
Gambia (S Hawkesworth, Y Sawo, AJC Fulford, GR
Goldberg, LMA Jarjou, A Prentice and SE Moore, unpub-
lished results), Australia(47) and Argentina(45) have shown
no association between maternal Ca supplementation
and offspring blood pressure at 5–10, 4–7 and 5–9 years
respectively (Table 6). Despite no overall association with
mean blood pressure, in Argentina the intervention was
found to be associated with a reduced risk of having high
systolic blood pressure (defined by age- and height-specific
cut-offs)(45).
In the Argentinian study an interaction was also found
between childhood BMI and maternal Ca supplementation
on offspring blood pressure(45). For children with a BMI
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Fig. 2. Interaction between body composition (percentage body fat)
and maternal protein–energy supplementation for systolic blood
pressure (BP) in Gambian adolescents at follow up. Values are
means with 2 SE represented by vertical bars. (Reproduced from
Hawkesworth et al.(34))
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above the mean at follow up the intervention was shown to
be associated with lower blood pressure(45). In the data
from The Gambia an interaction with body composition
was observed, but in the opposite direction; for individuals
in the highest quartile of percentage trunk fat at follow up
maternal Ca supplementation was found to be associated
with raised diastolic blood pressure (S Hawkesworth, Y
Sawo, AJC Fulford, GR Goldberg, LMA Jarjou, A Prentice
and SE Moore, unpublished results).
Interpretation and implications
The interpretation of the data presented in the present re-
view is that, to date, with the possible exception of multi-
ple micronutrients, there is little evidence to suggest that
supplementation of pregnant women affects their off-
spring’s risk factors for CVD. It is therefore important to
explore the reasons for this outcome. The first point that
should be highlighted is that there are very little data in
this area and more studies are required, including studies
with nutrients for which there is currently no evidence (e.g.
Fe, vitamin A, long-chain PUFA) or for which the evi-
dence base is weak (protein–energy).
The animal data in this field of DOHaD in relation to
CVD risk are extremely strong and many mechanisms have
been identified that explain the impact of nutrient restric-
tion during pregnancy on disease risk in the offspring(11,12).
It may therefore seem surprising that, to date, these find-
ings have not been replicated in human subjects. However,
the majority of animal studies involve interventions that
are at the extreme end of nutrient restriction; equivalent
treatments will not be given in human intervention studies
because they are both unethical and not relevant to real
life. In addition, animal studies have focused on restricting
nutrients whereas studies of human pregnancy are designed
to increase intake relative to control or placebo, therefore
making the results difficult to compare. An additional
explanation may be that the incremental nutrient require-
ments for human reproduction are very low compared with
other species (because human subjects have evolved to
have very slow pre- and postnatal growth rates) and the
developing fetus is protected by a number of evolved
adaptations(48).
One relevant issue for interpretation is that of sample
size. For example, in order to detect a difference of
2mmHg in systolic blood pressure (commonly recognised
Table 3. Characteristics of a Nepalese trial and follow-up study of maternal multiple-micronutrient supplementation
Reference
Original trial Osrin et al.(62)
Design Double-blind randomised controlled trial, 2002–4
Randomisation Computer-generated randomisation; allocation concealment
Participants Pregnant women attending antenatal clinic in Janakpur
Singleton pregnancies
Enrolled at £20 weeks of gestation
Supplement Tablets taken daily from enrolment until delivery
Intervention arm: fifteen multiple micronutrients (800mg vitamin A, 10 mg vitamin E,
5mg vitamin D, 1.4 mg thiamin, 1.4 mg riboflavin, 18 mg niacin, 1.9 mg vitamin B6,
2.6mg vitamin B12, 400 mg folic acid, 70 mg vitamin C, 30 mg Fe, 15 mg Zn, 2 mg Cu,
65mg Se, 150 mg iodine). Control arm: 60 mg Fe and 400 mg folic acid
Follow up Viadya et al.(40)
Date 2005–6
Age of offspring 2–3 years (mean 2.7 years)
Lost to follow up 917 of 1107 (83%) original children enrolled
Lost to follow-up associated with urban location and husbands who were salaried or
owned small business
Other confounders equally distributed
Outcomes Anthropometry and blood pressure (Omron electronic sphygmomanometer CEO197;
Omron, Milton Keynes, Bucks., UK)
Table 4. Effect of maternal micronutrient supplementation on CVD risk factors in the offspring in the follow up(40) to the original Nepalese
trial(62)
Outcome
Supplement* Control† Difference‡
Pn Mean SD n Mean SD Mean 95% CI
Systolic blood pressure (mmHg) 460 99.4 13.7 454 102 17.5 - 2.5 - 4.54, - 0.46 0.02
Diastolic blood pressure (mmHg) 460 62.1 12.8 454 63.4 14.7 - 1.3 - 3.09, 0.49 0.15
Triceps skinfold thickness (mm) 462 7.15 1.61 455 6.95 1.45 0.2 0.00, 0.40 0.05
*Intervention arm: fifteen multiple micronutrients (800mg vitamin A, 10 mg vitamin E, 5 mg vitamin D, 1.4 mg thiamin, 1.4 mg riboflavin, 18 mg niacin, 1.9 mg vitamin
B6, 2.6mg vitamin B12, 400mg folic acid, 70 mg vitamin C, 30 mg Fe, 15 mg Zn, 2 mg Cu, 65mg Se, 150 mg iodine).
†Control arm: 60 mg Fe and 400mg folic acid.
‡Unadjusted regression analysis.
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Table 5. Characteristics of trials and follow-up studies of maternal calcium supplementation
USA Argentina Australia The Gambia
Original trial Levine et al.(63) Belizan et al. (64) Crowther et al.(65) Jarjou et al.(66)
Design Randomised double-blind placebo-
controlled trial
Randomised double-blind placebo-
controlled trial
Randomised double-blind placebo-
controlled trial
Randomised double-blind placebo-
controlled trial
Randomisation Computer-generated randomisation;
allocation concealment
Computer generated randomisation;
allocation concealment
Computer generated randomisation,
stratified by centre; allocation
concealment
Random number tables, in blocks of four
to ensure seasonality equally
distributed; allocation concealment
Participants Nulliparous pregnant women attending
five medical centres
Enrolled between 13 and 20 weeks
of gestation
Passed a compliance test before
randomisation
Nulliparous pregnant women
attending three hospitals
Singleton pregnancies
Enrolled at 20 weeks of gestation
Nulliparous pregnant women from
five centres
Singleton pregnancy
Enrolled <24 weeks of gestation
Nulliparous and multiparous pregnant
women, from twenty-six villages in
rural Gambia
Singleton pregnancy
Enrolled <20 weeks of gestation
Supplement Four tablets taken daily until delivery
Intervention arm: 2g CaCO3
(500 mg per tablet)/d
Control arm: maize-starch placebo
Four tablets taken daily until delivery
Intervention arm: 2 g CaCO3
(500 mg per tablet)/d
Control arm: lactose placebo
Three tablets daily from 20 weeks
of gestation until delivery
Intervention arm: 1.8 g CaCO3
(600 mg per tablet)/d
Control arm: lactose placebo
Three tablets daily from 20 weeks of
gestation until delivery
Intervention arm: 1.5 g CaCO3
(500 mg per tablet)/d
Control arm; cellulose–lactose placebo
Follow up Hatton et al.(46) Belizan et al.(45) Hillier et al.(47) Hawkesworth et al.*
Date Not reported 1995–6 2000–2 2005–6
Age of offspring Two study periods: 3 months and
2 years
5–9 years (mean 7.1 years) 4–7 years 5–10 years (mean 7.4 years)
Lost to follow-up Study limited to one site
(representing 12% of the original trial)
3 months: 260 of 559 (47%) from
this site enrolled
2 years: fifty-seven of 559 (10%)
from this site enrolled
No data on lost-to-follow-up
differences
Study limited to one hospital
(representing 50% of original trial)
518 of 614 (84%) from this site
enrolled
Lost to follow up associated with
younger maternal age and lower
maternal blood pressure
179 of 456 (39%) original trial offspring
Lost to follow up associated with
younger mothers, with lower
Ca intake and lower compliance.
389 of 519 (75%) original trial offspring
No differences associated with lost
to follow-up
Outcomes Blood pressure (3 months:
sphygmomanometer with
ultrasonic amplification; 2 years
automated sphygmomanometer;
Critikon Tampa, FL, USA)
Left ventricular wall thickness
(echocardiography)
Blood pressure (Hg
sphygmomanometer)
Blood pressure (automated: Dinamap
845XT; Critikon Tampa, FL, USA)
Blood pressure (automated:
Omron 705IT; Omron, Milton Keynes,
Bucks., UK)
Body composition (Tanita BC-418MA;
Tanita UK Ltd, West Drayton,
Middlesex, UK; with population-specific
equations (61))
Triceps skinfold thickness
Fasted blood sample analysed for
glucose and insulin
*S Hawkesworth, Y Sawo, AJC Fulford, GR Goldberg, LMA Jarjou, A Prentice and SE Moore (unpublished results).
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as the population effect size associated with 1 kg higher
birth weight(7)) with 80% power at P<0.05 a study would
require a sample size of 948 (474 per arm) if for blood
pressure the SD is 11mmHg, a value reported recently for
Swedish military conscripts aged 18 years(49). Only a small
number of follow-up studies in the present review have
larger sample sizes than 474 per arm, highlighting again
the importance of further research in this area.
Another issue is that studies often suffer from large
losses to follow up (for example, see Hatton et al.(46)),
particularly if conducted in developed countries where
individuals are difficult to trace. It has recently been dis-
cussed that it is necessary to allow for much larger attrition
rates in DOHaD studies than are usually deemed to be
acceptable for randomised controlled trials involving
drugs(50). This requirement is mainly the result of the
practicalities of tracing individuals several years after their
mothers were enrolled into a trial. It has been argued that
provided information on attrition rates and the association
of characteristics with loss to follow up are reported, then a
judgement can be made on the quality of the data pre-
sented, even with large losses to follow up(50). The ma-
jority of studies presented in the current review were
conducted in developing country settings where close
family ties can mean that tracing subjects is less proble-
matic. This factor is reflected in the retention rates, most of
which are >60%.
A number of the original trials presented here have their
own limitations, which question the usefulness of associa-
ted follow-up data. Two of the protein–energy randomised
controlled trials were randomised at the community
level(25,33) and one of these trials (Institute of Nutrition of
Central America and Panama, Guatemala(26)) was unable
to take clustering into account for statistical analysis. Both
the trial in Guatemala(25) and that in Wales(30) provided
supplementation for infants and children as well as
pregnant women, making it impossible to distinguish be-
tween pre- and postnatal intervention. In the multiple-
micronutrient trial in Nepal(40) ‘control’ women received
Fe and folic acid supplements that contained double the
amount of Fe received by the multiple-micronutrient
group. The authors raise this factor as an issue; any effect
of supplementation could be the result of a lower Fe intake
rather than an increase in other micronutrients(40). Only the
Ca trials are true double-blind placebo-controlled trials and
even then the background Ca intakes vary greatly between
the populations studied.
Another factor that may explain the lack of association
seen between maternal supplementation and offspring
CVD risk is the timing of the follow-up studies. In the
majority of studies subjects are children or adolescents. It
may be that the effect of maternal supplementation only
becomes apparent when individuals reach adulthood. In
addition, the context of the study is important. The lack of
association seen in the studies in rural areas of The Gambia
(a transition country) may reflect the fact that the prevail-
ing nutritional exposures experienced postnatally have yet
to reach the levels seen in more affluent countries; such
levels may be required to reveal a disease response.
Finally, pregnancy represents just one time point within the
life course and may not be the optimum time to intervene
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to influence offspring health. Fetal nutrition is influenced
by the mother’s nutrient stores and by her own exposure
in utero(51); the window of opportunity during pregnancy
may actually be too late to affect offspring risk.
The final explanation is that it may actually be the early
postnatal environment that explains the inverse association
between birth weight and disease, a possibility that features
strongly in the DOHaD literature. It has been proposed that
this association, which is often only apparent after adjust-
ment for current size, can be explained by the rate of
growth of the individual after birth(18,52). The evidence
from randomised controlled trials of infant feeding indi-
cates that faster postnatal growth is associated with a range
of CVD risk factors including blood pressure(53) and insu-
lin resistance(54).
The data presented here may question the importance of
the fetal environment for the programming of human CVD
risk in later life. However, only some aspects of the fetal
environment have been reviewed, that of the maternal diet
insofar as it is affected by supplementation with protein–
energy, multiple micronutrients and Ca. Other exposures
such as maternal smoking(55), maternal age(55), stress(56) or
placental function(57) during pregnancy have not been
considered here and may influence fetal systems as they
develop. However, supplementation has the potential to
be more easily adopted into public health strategy than
altering other exposures that influence the fetal environ-
ment.
It has been suggested that the DOHaD field is of parti-
cular relevance to less-developed countries that carry the
greatest burden of growth-retarded infants whilst con-
currently experiencing an increasingly rapid nutrition
transition(58). Concerns have been raised that intervening in
pregnancy in such settings may act to increase the risk of
obesity and related disorders(59). Perhaps one of the posi-
tive conclusions that can be drawn from the present review
is that maternal interventions during pregnancy do not
seem to promote adverse CVD risk in the offspring, at least
within the age-groups presented here. Furthermore, sup-
plementation during pregnancy confers short-term benefits,
and may confer long-term benefits, to the offspring that are
outside of the scope of the review. For example, in Ban-
gladesh there is some evidence that food and multiple-
micronutrient supplementation of undernourished women
during pregnancy may improve offspring cognitive devel-
opment(41).
Concluding remarks
Conducting follow-up studies of offspring born to mothers
who have participated in supplementation trials during
pregnancy will provide a useful evidence base for the
DOHaD field. To date there is little evidence to suggest
that maternal protein–energy or Ca supplementation
affects offspring CVD risk factors (blood pressure,
body composition, fasting glucose), but further data are
required. One study of the impact of maternal multiple-
micronutrient supplementation suggests an effect on off-
spring systolic blood pressure, but requires replication in
other settings.
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